Searchable abstracts of presentations at key conferences in endocrinology

ea0099p92 | Endocrine-Related Cancer | ECE2024

How well does ‘real world’ management of Immune check point inhibitor induced hypophysits (ICI-Hp) reflect the European Society of Endocrinology (ESE) 2023 clinical practice guidelines (CPG)?: Experience from a single tertiary care centre

Mathara Diddhenipothage Shani Apsara Dilrukshi , Warden Jacqui , Herbert Katie , Pofi Riccardo , Coupe Nicholas , Payne Miranda , Tomlinson Jeremy W , Turner Helen

Introduction: Hypophysitis (Hp) is a serious adverse effect (AE) of Immune check-point inhibitor (ICI) therapy in malignancy. We evaluated 6 yeas of clinical expereince with ICI against the recent ESE CPG 2023 which provides practical guidance on the management of this condition based on up-to-date evidence.Methods: A quality improvement project (QIP) included all patients with ICI-Hp (n=17) referred to a dedicated Endocrine-ICI clinic (January ...

ea0077op6.1 | Endocrine Cancer and Late Effects | SFEBES2021

Incidental findings are common, but rarely clinically significant, in patients with Neuroendocrine Tumours undergoing Gallium68 Dotatate PET CT; results from a one year retrospective review

Garrahy Aoife , Tadman Mike , Slater Viv , Moore Niall , Coupe Nicholas , Weaver Andrew , Soonawalla Zahir , Patel Neel , May Christine , Jafar Mohammadi Bahram

Gallium68-Dotatate PET-CT is a somatostatin-receptor (SSTR) based imaging modality employed in the diagnosis and follow-up of Neuroendocrine Tumours (NET). We set out to investigate the incidence of incidental findings, some of which are related to SSTR expression, in our NET patient cohort in Oxford University Hospital. Sixty-eight patients underwent Gallium68-Dotatate PET-CT between June 2020 and June 2021. 40 patients (59%) were female, and median age ...